叶酸受体及其在肿瘤核医学中的应用

邢诗安

叶酸受体及其在肿瘤核医学中的应用

邢诗安

文章导航 > 国际放射医学核医学杂志 > 2002, 26 > 6: (257-259)

引用本文:

Citation:

叶酸受体及其在肿瘤核医学中的应用

邢诗安

430022 武汉, 华中科技大学同济医学院附属协和医院核医学科

作者简介: 邢诗安(19795-),女,湖南浏阳人,硕士研究生,主要从事肿瘤核医学方面的工作。;

中图分类号: R817.4

Folate receptor and the application in tumor nuclear medicine

XING Shi-an

Department of Nuclear Medicine, Union Hospital, Tongji medical college, Huazhong University of Science and Technology, Wuhan 430022, China
CLC number: R817.4

摘要: 叶酸受体是一种在肿瘤细胞膜表面高度表达的蛋白膜受体,有α和β两种亚型。来源于上皮组织的癌组织高度表达α亚型受体,非上皮来源的癌组织主要表达β亚型受体,两种亚型受体对叶酸及其类似物都有很高的亲和力。叶酸受体在几乎所有的卵巢癌和大部分的恶性肿瘤如乳腺癌、宫颈癌、结肠癌、直肠癌、鼻咽癌等中都有表达,同时在正常组织的表达又高度保守。通过对其分类、结构、染色体定位、分布、配体及其在肿瘤核医学中应用的研究,将有助于肿瘤的早期诊断和针对肿瘤细胞的靶向性治疗。
- 肿瘤 /
- 叶酸 /
- 受体显像
Abstract: The folate receptor is a membrane protein overexpressed in tumor cells.Two folate receptor isoforms have been identified in humans by the modern molecular biology, α and β.The type α receptor is frequently overexpressed in epithelial-lineaged tumors and the type β in nonepithelial-derived tumors.Both isoforms show a high affinity for folic acid.The folate receptor is overexpressed in approximately 100% of other ovarian carcinomas and a wide variety of other human cancers,including breast,cervical,colorectal and nasopharyngeal tumors,while being highly restricted in most normal tissues.The studies of folate receptor in the isoforms,structures,gene mapping,distribution,ligand and application in trmor nuclear medicine will be helpful in the early diagnosis and treatment of tumors.
- tumor /
- folate receptor /
- receptor imaging
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Ratnam M, Marquardt H, Duhring JL, et al. Homologous membrane folate binding proteins in human placenta:cloning and sequence of a cDNA[J]. Biochemistry, 1989, 28(20):8249-8254.
[2]	Lacey SW, Sanders JM, Rothberg KG, et al. Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl-phosphatidylinositol[J]. J Clin Invest, 1989, 84(2):715-720.
[3]	Coney LR, Tomassetti A, Carayannopoulos L, et al. Cloning of a tumor-associated antigen:MOv18 and MOv19 antibodies recognize a folate-binding protein[J]. Cancer Res, 1991, 51(22):6125-6132.
[4]	Antony AC. The biological chemistry of folate receptors[J]. Blood, 1992, 79(11):2807-2820.
[5]	Weitman SD, Weinberg AG, Coney LR, et al. Cellular localization of the folate receptor:potential role in drug toxicity and folate homeostasis[J]. Cancer Res, 1992, 52(23):6708-6711.
[6]	Ross JF, Chaudhuri PK, Ratnam M. Diffierential regulation of folate receptor isoforms in normal malignant tissues in vivo and in established cell lines[J]. Cancer, 1994, 73:2432-2443.
[7]	Wang X, Shen F, Freisheim JH, et al. Differential stereospicifities and affinity of folate receptor isoforms for folate compounds and antifolates[J]. Biochem Pharmacol, 1992, 44:1898-1901.
[8]	Visser GW, Klok RP, Gebbinck JW, et al. Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN[J]. J Nucl Med, 2001, 42(3):509-519.
[9]	Casalini P, Luison E, Menard S, et al. Tumor pretargeting:role of avidin/streptavidin on monoclonal antibody internalization[J]. J Nucl Med, 1997, 38(9):1378-1381.
[10]	Crippa F, Bolis G, Seregni E, et al. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18:clinical results in patients with minimal residual disease of ovarian cancer[J]. Eur J Cancer, 1995, 31A(5):686-690.
[11]	Leamon CP, Low PS. Delivery of macromolecules into living cells:a method that exploits folate receptor endocytosis[J]. Proc Natl Acad Sci USA, 1991, 88(13):5572-5576.
[12]	Mathias CJ, Wang S, Lee RJ, et al. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate[J]. J Nucl Med, 1996, 37(6):1003-1008.
[13]	Mathias CJ, Wang S, Waters DJ, et al. Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical[J]. J Nucl Med, 1998, 39(9):1579-1585.
[14]	Mathias CJ, Hubers D, Low PS, et al. Synthesis of ⁹⁹Tc^m-DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical[J]. Bioconjug Chem, 2000, 11(2):253-257.
[15]	Guo W, Hinkle GH, Lee RJ. ⁹⁹Tc^m-HYNIC-folate:a novel receptor-based targeted radiopharmaceutical for tumor imaging[J]. J Nucl Med, 1999, 40(9):1563-1569.
[16]	Wang S, Lee RJ, Cauchon G, et al. Delivery of antisense oligodeoxynucleotides against the human epidermal growth factor receptor into cultured KB cell with liposome conjugated to folate via polyethylene glycol[J]. Proc Natl Acad Sci USA, 1995, 92:3312-3318.
[17]	Ni S, Stephenson SM, Lee RJ. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells[J]. Anticancer Res, 2002, 22(4):2131-2135.

[1]	张春丽 , 王荣福 . 肿瘤受体显像. 国际放射医学核医学杂志, 2000, 24(3): 124-127,141.
[2]	王雪鹃 , 张梅颖 , 林保和 . 肿瘤血管活性肠肽受体显像. 国际放射医学核医学杂志, 2001, 25(2): 65-69.
[3]	李林 , 谭天秩 . 层粘素受体显像. 国际放射医学核医学杂志, 1999, 23(6): 245-247.
[4]	李前伟 , 谭天秩 , 林汉 . 放射性核素标记血管活性肠肽的肿瘤受体显像. 国际放射医学核医学杂志, 1996, 20(3): 124-128.
[5]	匡安仁 , 谭天秩 . 基本的受体显像数学模型和方法. 国际放射医学核医学杂志, 1997, 21(1): 21-25.
[6]	段炼 , 李险峰 . 甲状腺相关眼病与生长抑素受体显像. 国际放射医学核医学杂志, 2005, 29(3): 108-111.
[7]	张军 . ¹¹C-flumazenil受体显像在缺血半暗带研究中的进展. 国际放射医学核医学杂志, 2004, 28(6): 246-249.
[8]	施可欣 , 张晓辉 , 金晨涛 , 田梅 . PET受体显像在肥胖人群神经功能改变成像中的作用. 国际放射医学核医学杂志, 2019, 43(6): 523-527. doi: 10.3760/cma.j.issn.1673-4114.2019.06.006
[9]	邱春 , 管一晖 . 5-羟色胺受体显像剂在神经系统疾病及脑功能研究中的应用. 国际放射医学核医学杂志, 2011, 35(2): 73-80, 127. doi: 10.3760/cma.j.issn.1673-4114.2011.02.003
[10]	柳江燕 , 陈雪红 . 肿瘤受体显像及介导靶向治疗的研究进展. 国际放射医学核医学杂志, 2005, 29(6): 258-260.

点击查看大图

计量

文章访问数: 1177
HTML全文浏览量: 154
PDF下载量: 2

叶酸受体及其在肿瘤核医学中的应用

邢诗安

作者简介:邢诗安(19795-),女,湖南浏阳人,硕士研究生,主要从事肿瘤核医学方面的工作。

430022 武汉, 华中科技大学同济医学院附属协和医院核医学科

收稿日期: 2001-12-03

关键词:

肿瘤 /
叶酸 /
受体显像

摘要: 叶酸受体是一种在肿瘤细胞膜表面高度表达的蛋白膜受体,有α和β两种亚型。来源于上皮组织的癌组织高度表达α亚型受体,非上皮来源的癌组织主要表达β亚型受体,两种亚型受体对叶酸及其类似物都有很高的亲和力。叶酸受体在几乎所有的卵巢癌和大部分的恶性肿瘤如乳腺癌、宫颈癌、结肠癌、直肠癌、鼻咽癌等中都有表达,同时在正常组织的表达又高度保守。通过对其分类、结构、染色体定位、分布、配体及其在肿瘤核医学中应用的研究,将有助于肿瘤的早期诊断和针对肿瘤细胞的靶向性治疗。